Periventricular haemorrhage and tocolytic therapies

Resting heart rate does not predict growth in preterm infants

BACKGROUND

Previous reports indicate that preterm infants with higher baseline heart rate (HR) have greater weight gain than preterm infants with lower baseline HR. To verify this correlation and the potential utility of resting HR as a bench mark for risk of extrauterine growth restriction (EUGR), we studied preterm infants born between 32 and 36weeks gestation. Earlier gestation infants (27 to 31weeks) were included.

METHODS

In retrospective chart review we collected heart rate (HR) and growth data on 156 infants between 27.0 and 34.0weeks gestation from birth to hospital discharge.

RESULTS

There was a significant increase in weight gain from day 10 of life in infants with higher resting HR compared to infants with lower resting HR. However, upon controlling for birth weight and gestational age, there was no significant relationship between HR and weight gain for any gestational age group of premature infants.

CONCLUSIONS

Contrary to previous reports, there was no significant relationship between HR and growth at any gestational age after controlling for birth weight and gestational age. It is important to continue to search for a clinical marker of risk for poor growth in preterm infants and to give an opportunity for nutritional interventions which may support better growth and developmental outcomes.

Extrauterine growth restriction: a review of the literature

Extrauterine growth restriction (EUGR) is a common condition in very low birth weight (VLBW) preterm infants (< or = 1,500 g). Most affected infants have a birth weight that is average for gestational age, but by the time of hospital discharge have a weight that is less than the tenth percentile for corrected gestational age. EUGR is the most frequent morbidity among VLBW survivors at their time of discharge from the hospital. Studies to elucidate the causes of EUGR have been inconclusive. Recent research has found an association between EUGR, developmental outcomes, and long-term morbidity. Low birth weight has also been associated with chronic diseases later in life. These findings emphasize the critical nature of understanding the phenomenon of EUGR and ways it can be prevented.

Therapeutic efficacy and mechanism of action of ethamsylate, a long-standing hemostatic agent

Ethamsylate (2,5-dihydroxy-benzene-sulfonate diethylammonium salt) is a synthetic hemostatic drug indicated in cases of capillary bleeding. This review covers more than 40 years of intensive clinical and fundamental research with ethamsylate. First, we summarize the large medical literature concerning its clinical efficacy. Of these, well-controlled clinical trials clearly showed the therapeutic efficacy of ethamsylate in dysfunctional uterine bleeding, with the magnitude of blood-loss reduction being directly proportional to the severity of the menorrhagia. Other well-controlled clinical trials showed therapeutic efficacy of ethamsylate in periventricular hemorrhage in very low birth weight babies and surgical or postsurgical capillary bleeding. Second, we review the numerous investigations performed to elucidate the mechanism of action of ethamsylate. Ethamsylate acts on the first step of hemostasis by improving platelet adhesiveness and restoring capillary resistance. Recent studies showed that ethamsylate promotes P-selectin-dependent, platelet adhesive mechanisms. Finally, we compare ethamsylate with other recent hemostatic agents. It is suggested that the place of ethamsylate as a hemostatic agent is that of a mild but well-tolerated drug, particularly useful in dysfunctional uterine bleeding when contraception is not needed.